Retatrutide Benefits: What Clinical Research Shows

Key takeaways

• Weight loss of 24.2% at 48 weeks (phase 2) and 28.7% at 68 weeks (phase 3) on the 12 mg dose
• Liver fat reduction of up to 82% in patients with MASLD, with 86% reaching normal liver fat levels
• 72% of participants with prediabetes reverted to normal blood sugar levels
• 75% reduction in knee osteoarthritis pain in the TRIUMPH-4 trial
• The glucagon receptor component adds benefits not seen with single or dual agonist medications

Retatrutide is the first triple agonist to produce phase 3 clinical data. Its benefits come from activating three receptors that each contribute something different: GLP-1 suppresses appetite, GIP improves metabolic signaling, and glucagon increases energy expenditure and liver fat oxidation [1].

That combination has produced benefits across several areas. Some are direct (weight loss, liver fat reduction) and some are downstream effects of the weight loss itself (improved blood pressure, joint pain relief). Here’s what the clinical data actually shows, with the specific numbers behind each claim.

Weight loss

This is the headline benefit and the one with the strongest data.

Phase 2 trial (Jastreboff et al., 2023): 338 adults with obesity, 48-week treatment [1]:

• 12 mg dose: 24.2% average body weight loss
• 8 mg dose: 22.8%
• 4 mg dose: 17.1%
• Placebo: 2.1%

At the 12 mg dose, that translates to an average of 58 pounds. For a detailed timeline of results, see our before-and-after page.

Phase 3 TRIUMPH-4 (December 2025): 68-week treatment in adults with obesity and knee osteoarthritis [2]:

• 12 mg dose: 28.7% body weight loss (26.6% placebo-adjusted)
• Average absolute weight loss: 71.2 pounds

Response rates tell an even clearer story. At 48 weeks on 12 mg:

• 100% of participants lost at least 5% of body weight
• 93% lost at least 10%
• 83% lost at least 15%

For comparison, the best published data for semaglutide (STEP 1 trial) showed 14.9% weight loss at 68 weeks, and tirzepatide (SURMOUNT-1) showed 22.5% at 72 weeks. Retatrutide’s numbers are higher across every metric [1, 3, 4].

The weight loss at 48 and 68 weeks hadn’t fully plateaued, suggesting that longer treatment durations may produce even greater reductions.

Liver fat reduction

This may be retatrutide’s most distinctive benefit, and it comes directly from the glucagon receptor component that other GLP-1 medications lack.

A phase 2a trial published in Nature Medicine (Sanyal et al., 2024) tested retatrutide in patients with metabolic dysfunction-associated steatotic liver disease (MASLD, the condition formerly called NAFLD) [5]:

• Liver fat reduction of up to 82% at 24 weeks
• 86% of participants on 12 mg achieved normal liver fat levels (below 5%)
• More than 85% had complete resolution of steatosis
• Biomarkers of liver fibrosis (K-18, pro-C3) also improved

This matters because MASLD affects roughly 30% of the U.S. adult population, and no drug is currently FDA-approved for it. Semaglutide and tirzepatide reduce liver fat to some degree through weight loss, but the magnitude of retatrutide’s effect is substantially larger. The difference is likely driven by glucagon receptor activation, which directly promotes hepatic fatty acid oxidation [5].

Blood sugar control

Retatrutide’s effects on blood glucose go beyond what weight loss alone would explain.

In the phase 2 obesity trial [1]:

• 72% of participants who had prediabetes at baseline (HbA1c 5.7-6.4%) reverted to normoglycemia
• Fasting glucose levels decreased significantly across all dose groups
• Insulin sensitivity improved in a dose-dependent manner

A separate phase 2 trial specifically in adults with type 2 diabetes (Rosenstock et al., 2023) showed dose-dependent HbA1c reductions, confirming that retatrutide has meaningful glycemic benefits beyond weight loss [6].

The three-receptor mechanism contributes to blood sugar control in complementary ways:

• GLP-1: stimulates insulin secretion when blood sugar is elevated and suppresses glucagon secretion (paradoxically, the exogenous glucagon agonism is counterbalanced by GLP-1-driven insulin increases)
• GIP: amplifies glucose-stimulated insulin secretion
• Glucagon: while it raises hepatic glucose output in isolation, the net effect when combined with GLP-1 and GIP is improved glycemic balance, not hyperglycemia

This three-way mechanism may explain why 72% of prediabetic participants reverted to normal blood sugar, a conversion rate higher than what’s been reported with single or dual agonists [1, 6].

Joint pain and osteoarthritis relief

The TRIUMPH-4 trial was specifically designed to test retatrutide in adults with obesity and knee osteoarthritis [2]:

• 75% reduction in knee osteoarthritis pain scores
• Improved physical function measures
• Effects exceeded those seen with semaglutide for knee OA (which showed 42% pain reduction in a previous trial)

Some of this improvement comes from weight loss reducing mechanical stress on the joints. Losing 70+ pounds means substantially less load on the knees with every step. But the degree of pain improvement (75%) exceeds what weight loss alone typically achieves, suggesting possible anti-inflammatory effects from the receptor activation itself [2].

For more on peptides and joint health, see our guides on peptides for joint pain and BPC-157 for arthritis.

Cardiovascular risk reduction

The TRIUMPH-4 trial reported reductions in blood pressure and cardiovascular risk factors, though detailed numerical data hasn’t been published yet in a peer-reviewed paper [2].

Based on what we know from the phase 2 trial and the general effects of the three targeted receptors [1]:

• Blood pressure decreased with weight loss
• Lipid profiles improved
• Inflammatory markers trended downward

A dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes) is underway to determine whether retatrutide reduces major cardiovascular events (heart attack, stroke, cardiovascular death). This trial will take years to complete but is necessary to establish cardiovascular benefit, similar to how the SELECT trial established cardiovascular benefits for semaglutide [2].

Benefits unique to triple agonism

Several of retatrutide’s benefits appear to come specifically from the glucagon receptor component that isn’t present in semaglutide or tirzepatide [7]:

Increased energy expenditure. Glucagon receptor activation raises resting metabolic rate. This means the body burns more calories even at rest, contributing to weight loss beyond what appetite suppression alone achieves. Dual agonists don’t produce this effect.

Enhanced liver fat oxidation. The 82% liver fat reduction in the MASLD trial is dramatically higher than what semaglutide (roughly 30-40%) or even tirzepatide (roughly 50%) achieve. Glucagon directly stimulates the liver to oxidize fatty acids.

Potentially better body composition. While detailed body composition data from retatrutide trials hasn’t been published, the metabolic rate increase from glucagon agonism theoretically preserves lean mass better than pure appetite suppression. This remains to be confirmed with published DXA or body composition data.

What the data doesn’t show yet

Being honest about the limits of current evidence:

Long-term safety. The longest published data is 68 weeks. Medications taken for years need years of safety data. A new side effect signal (dysesthesia) appeared in phase 3 that wasn’t seen in phase 2, which illustrates why longer studies matter.

Weight regain after stopping. No published data exists on what happens after discontinuing retatrutide. Based on other GLP-1 medications, weight regain is likely without continued treatment.

Real-world effectiveness. Clinical trial participants receive structured support. Real-world results typically fall below trial averages.

Cancer risk. GLP-1 receptor agonists carry theoretical thyroid cancer risk based on rodent studies. Retatrutide hasn’t been studied long enough to evaluate this in humans.

Frequently asked questions

What is the main benefit of retatrutide?▼

The primary demonstrated benefit is weight loss: 24-29% of body weight over 48-68 weeks. Secondary benefits include liver fat reduction (up to 82%), blood sugar normalization (72% prediabetes reversion), and joint pain relief (75% reduction in knee OA pain) [1, 2, 5].

Is retatrutide better than semaglutide?▼

For weight loss, the clinical trial data shows roughly 60-80% more weight loss with retatrutide compared to semaglutide. But semaglutide is FDA-approved with extensive long-term safety data, while retatrutide is investigational. “Better” depends on whether you prioritize maximum efficacy or established safety record. See our weight loss peptides guide for a full comparison.

Does retatrutide help with fatty liver?▼

Yes. The phase 2a MASLD trial showed liver fat reductions of up to 82%, with 86% of participants on 12 mg reaching normal liver fat levels. This is the strongest liver fat reduction reported for any incretin-based medication and appears to be driven by the glucagon receptor component [5].

How quickly do retatrutide benefits appear?▼

Appetite reduction typically begins within the first 1-2 weeks. Measurable weight loss starts by weeks 2-4. Metabolic improvements (blood sugar, insulin sensitivity) develop over the first 3-6 months. The full extent of weight loss benefits takes 12+ months to materialize based on current trial data [1].

Can retatrutide help with type 2 diabetes?▼

Phase 2 data in adults with type 2 diabetes showed dose-dependent HbA1c reductions and weight loss. In the obesity trial, 72% of prediabetic participants reverted to normoglycemia. Phase 3 diabetes trials are ongoing. However, retatrutide is not approved for diabetes treatment, and patients with type 2 diabetes should discuss all treatment options with their endocrinologist [1, 6].

Does retatrutide build muscle?▼

Retatrutide has not been shown to build muscle. It is a weight loss and metabolic medication. The glucagon component may theoretically help preserve lean mass during weight loss by increasing metabolic rate, but body composition data hasn’t been published in detail. Resistance training during treatment is recommended to minimize muscle loss during weight loss [1].

References

1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. N Engl J Med. 2023;389(6):514-526. doi:10.1056/NEJMoa2301972
2. Eli Lilly. Lilly’s triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs in first successful Phase 3 trial. Press release. December 11, 2025.
3. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384(11):989-1002.
4. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
5. Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30:2037-2048.
6. Rosenstock J, Frias JP, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes. Lancet. 2023;402(10401):529-544.
7. Finan B, Yang B, Ottaway N, et al. A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents. Nat Med. 2015;21(1):27-36.
8. Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: from discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247. doi:10.1016/j.cmet.2022.07.013